The advent of a new pseudoephedrine product to combat methamphetamine abuse
| Autor: | Albert W. Brzeczko, Ronald L. Leech, Jeffrey G. Stark |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Nexafed
Amphetamine-Related Disorders Street drugs Internet privacy Medicine (miscellaneous) Nonprescription Drugs Methamphetamine medicine Humans Technology Pharmaceutical Methamphetamine abuse Product (category theory) Clandestine laboratories Illicit Drugs business.industry Limiting Pseudoephedrine Nasal decongestant Nasal Decongestants Psychiatry and Mental health Clinical Psychology Impede technology Anesthesia extraction Central Nervous System Stimulants Pseudoefedrina methamphetamine abuse business Regular Articles Tablets medicine.drug |
| Zdroj: | The American Journal of Drug and Alcohol Abuse |
| ISSN: | 1097-9891 0095-2990 |
| DOI: | 10.3109/00952990.2013.821476 |
| Popis: | Background: The personal and societal effects of methamphetamine abuse are well documented. The ease of accessibility to methamphetamine and the quality of the “high” it produces makes the drug highly desired by its abusers. Over time, many methamphetamine users will also become methamphetamine cooks, where pseudoephedrine in over-the-counter cold products is converted to methamphetamine through a simple, albeit extremely dangerous, process. New laws limiting access to these products have had limited success. No existing commercial pseudoephedrine products offer significant impediments to slow or limit the extraction and conversion of pseudoephedrine in clandestine methamphetamine laboratories. Objective and Methods: A new pseudoephedrine 30 mg tablet product using Impede technology (Nexafed®) to deter methamphetamine production has recently been introduced into the marketplace. Using methods designed to mimic clandestine laboratory processes, the ability of this product to disrupt extraction and conversion of pseudoephedrine to methamphetamine yet provide therapeutic effectiveness was evaluated. Results: Impede™ technology tablets limited the extraction and/or conversion of pseudoephedrine to methamphetamine when compared to a commercially marketed pseudoephedrine product (Sudafed®). Nexafed® tablets were also shown to be bioequivalent to the same control product, thus ensuring therapeutic equivalence. Conclusions: With the advent of new pseudoephedrine products in the marketplace with features to limit the extraction and conversion of pseudoephedrine to methamphetamine, new tools are now available to minimize the clandestine manufacture of the drug and potentially limit its social impact. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |